

SYNBIOTIC THERAPY INCREASES ERADICATION RATE IN HELICOBACTER PYLORI ERADICATION

ÖNDER ŞAHİN¹, ATAKAN YEŞİL², EBUBEKİR ŞENATEŞ³, MEHMET FATİH AKDOĞAN⁴, SEVKİ KONÜR⁴, EMRULLAH ERDEM², MEHMET SINAN DAL⁵, TARKAN KARAKAN⁶

¹Department of Neurology, Neuromuscular Patology Unit, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey - ²Haydarpaşa Numune Education and Research Hospital, Department of Gastroenterology, Turkey - ³Department of Gastroenterology, Dicle University Medical Faculty, Diyarbakir, Turkey - ⁴Department of Internal medicine, Haydarpaşa Numune Education and Research Hospital, Istanbul, Turkey - ⁵Department of Hematology, Dicle University Medical Faculty, Diyarbakir, Turkey - ⁶Department of Gastroenterology, Gazi University Hospital Ankara, Turkey

[Symbiotici per *H. pylori*]

ABSTRACT

Background: Probiotics are used in combinations of *H. pylori* eradication regimens with variable results. Many strains tested had shown positive effects on side effect profiles. However, a clear effect on eradication rate is studied thoroughly. We aimed to investigate the beneficial effect of a synbiotic combination in clarithromycin-based triple eradication therapy.

Methods: Ninety-two patients who were infected with *H. pylori* (confirmed via endoscopic biopsy) were randomized into two groups: those undergoing standard triple treatment (control group (rabeprozoil plus amoksisilin plus clarithromycin bid) n=49) and those receiving synbiotic (triple plus synbiotic bid group n=43). The synbiotic product contained lactobacillus, bifidobacterium and enterococcus. The 13C-breath test was performed at least 6 weeks after completing both therapy regimens.

Results: In the synbiotic group, 3 of the patients complained of metallic taste (7.0%), 1 complained of diarrhea (2.3%), 3 had nausea (7.0%), 2 had gas (4.7%), 3 experienced vomiting (7.0%) and 1 had constipation (2.3%). In the control group, 3 of the patients experienced a metallic taste (6.3%), 7 had diarrhea (14.6%), 5 had nausea (10.4%), 3 had intestinal bloating (6.3%), 3 experienced vomiting (6.3%) and 1 had constipation (2.1%). There was no significant difference between the two groups. However, side effect intensity and eradication rates were significantly different between the groups ($p < 0.05$). The eradication rate in the synbiotic group was 88.4%, while it was 68.8% in the control group ($p < 0.05$).

Conclusion: The addition of synbiotic to triple therapy decreases the rate of antibiotic-related side effects. It also increases *H. pylori* eradication rates in clarithromycin-based triple therapy.

Key words: *Helicobacter pylori*, eradication, probiotics, synbiotics, lactobacillus, bifidobacteria.

Received April 20, 2013; Accepted May 08, 2013

Introduction

Helicobacter pylori (*H. pylori*) is a gram negative bacterium that has a well-known role in the pathogenesis of gastric and duodenal ulcers, gastric cancer, and gastric lymphomas⁽¹⁾. The International Agency for Research on Cancer declared *H. pylori* a class I carcinogen in 1994⁽²⁾.

Although several different treatment regimens have been evaluated for its successful eradication, the use of proton pump inhibitors with amoxicillin and clarithromycin remains the recommended treatment for *H. pylori* infection⁽³⁾.

However, increased antibiotic resistance, especially to clarithromycin has significantly lowered the effectiveness of this treatment⁽⁴⁾. To solve this problem, alternative regimens including new antimicrobials such as levofloxacin⁽⁵⁾ and moxifloxacin⁽⁶⁾ have been used. In addition, antibiotic-associated side effects such as metallic taste, bloating, nausea, vomiting, and diarrhea are major factors of patient noncompliance and treatment failures⁽⁷⁾.

Probiotics are living microbial species that can have favorable effects on the bowel micro-ecology and can improve health conditions if given in adequate doses⁽⁸⁾.

Recent studies have hypothesized that probiotics can inhibit *H. pylori* infection using three main mechanisms. First, lactic acid, which is produced by some strains of probiotics, can inhibit *H. pylori* urease by lowering gastric pH. Second, the bacteriocin, which is produced by the probiotics, can kill *H. pylori*, and third, probiotics can inhibit the adherence of *H. pylori* to the gastric epithelium⁽⁹⁻¹¹⁾. Although several studies have shown that the use of probiotics during first-line therapy can improve *H. pylori* eradication rates via these mechanisms, it is still controversial. Opposing studies discuss that the beneficial effects of probiotics are strain specific, and that different strains can cause misleading results^(12,13).

A prebiotic is a selectively fermented ingredient that allows specific changes, both in the composition and/or activity in the gastrointestinal microflora, that confers benefits upon its hosts well-being and health. Synergistic combinations of pro- and prebiotics are called synbiotics⁽¹⁴⁾.

In this study, for the first time, we use synbiotics with clarithromycin-based triple therapy to show beneficial effects on *H. pylori* eradication rates and side effects.

Materials and Methods

Ninety-two patients diagnosed with an *H. pylori* infection participated in this study between June and September 2012. Those patients aged below 18 or above 85 years, who previously underwent treatment for *H. pylori*, who had a suspected or confirmed malignancy, acute infection, a history of gastric operation, and/or pregnancy were excluded from the study.

This randomized, prospective, open-labeled study was performed at Haydarpasa Numune Research and Education Hospital located in İstanbul.

Ninety-two patients who were infected with *H. pylori* (confirmed via endoscopic biopsy) were randomized into two groups: those undergoing standard triple treatment (control group (rabeprazole plus amoksisilin plus clarithromycin bid) $n=49$) and those receiving synbiotic (triple therapy plus synbiotic bid group $n=43$). The synbiotic product was used 2 times a day. Those patients receiving synbiotic began treatment with the synbiotic product 3 days before beginning eradication therapy. After these 3 days, they received triple plus synbiotic therapy for 14 days.

The synbiotic product contained lactobacillus, bifidobacterium and enterococcus. The ¹³C-breath test was performed at least 6 weeks after completing both therapy regimens.

At the time of therapy, all patients were informed of the side effects, were motivated to complete therapy, and a questionnaire form was given to all patients, which included the probable side effects of eradication treatment. After two weeks of the eradication treatment, compliance and side effects for both groups were evaluated by the same gastroenterologist. Patients were asked to explain all possible side effects and all forms were carefully filled out. As a result, the side effects and compliance were compared, and 6 weeks after the eradication therapy, eradication rates were compared between both groups.

Statistical analysis

In the study, Chi-Square and Mann Whitney-U tests were used for difference analysis of the non-parametric parameters of the participants. Results were considered statistically significant for P values less than 0.05.

Results

Demographic parameters and differences between the group using synbiotics and those in the conventional therapy group (not using synbiotics) are presented in (Table 1).

As seen in Table 1, 51.2% of those in the probiotic group were female and 48.8% were male. There were 47.9% females and 52.1% males in the control group. There were no significant differences between patient groups based on their gender ($p=0.757$), history of smoking ($p=0.450$), alcohol use ($p=0.932$) and ulcer type ($p=0.439$). Clinical properties and differences between the two groups are given in Table 2.

Table 2 shows that although two of the patients in the synbiotic group (4.6%) were not under follow-up, there were 14 patients in the control group (29.2%) that were not followed-up. However, there was no significant difference between the groups ($p>0.05$), indicating that follow-up of patients in both groups was similar.

In the synbiotic group, 3 of the patients complained of metallic taste (7.0%), 1 complained of diarrhea (2.3%), 3 had nausea (7.0%), 2 had intestinal bloating (4.7%), 3 experienced vomiting (7.0%)

Parameters	Group				p
	Probiotic		Control		
	n	%	n	%	
Gender					
Female	22	51.2	23	47.9	0.757*
Male	21	48.8	25	52.1	
Smoking					
Yes	7	16.3	5	10.4	0.450**
No	36	83.7	38	79.2	
Ex-smoker	0	0	5	10.4	
Alcohol					
Yes	6	14.0	7	14.6	0.932*
No	37	86.0	41	85.4	
Ulcer Type					
Gastric	3	7.0	4	8.3	0.439**
Duodenal	8	18.6	12	25.0	
Nonulcer	32	74.4	32	66.7	

Table 1: Demographic Properties of the Patient Groups.

*Chi-Square statistics at 0.05 significance level

**Mann Whitney-U Test at 0.05 significance level

and 1 had constipation (2.3%). In the control group, 3 of the patients experienced a metallic taste (6.3%), 7 had diarrhea (14.6%), 5 had nausea (10.4%), 3 had intestinal bloating (6.3%), 3 experienced vomiting (6.3%) and 1 had constipation (2.1%). There was no significant difference between these groups.

However, side effect intensity and eradication rates were significant between the groups ($p < 0.05$). The patients in the synbiotic group expressed that the side effects they experienced were not significant and none of the patients in that group ranked their side effect range. The eradication rate in the synbiotic group was 88.4%, while it was 68.8% in the control group ($p < 0.05$).

Discussion

After the World Health Organization classified *H. pylori* as a class I carcinogen in 1994 for gastric cancer, many studies have focused on the eradication of *H. pylori* infection⁽²⁾. Although antibiotic resistance, primarily to clarithromycin is increasing, PPI treatment combined with amoxicillin and clarithromycin remains the recommended first line treatment for *H. pylori* infection (according to the Maastricht IV. guideline)⁽³⁾. This guideline also suggests that 14 days of therapy is superior to 7 days of therapy⁽³⁾. In Turkey, the most popular prescribed

regimen is the same⁽¹⁵⁾. However, in other developing countries, *H. pylori* eradication rates are being reduced due to increasing clarithromycin resistance and noncompliance to therapy because of side effects⁽¹⁶⁾.

Parameters	Group				p
	Probiotic		Control		
	n	%	n	%	
Follow-up					
Followed	41	95.3	34	70.8	0.267**
Not adapted	1	2.3	3	6.3	
Lost to follow up	1	2.3	4	8.3	
Discontinued treatment due to side effects			7	14.6	
Side Effects					
None	30	69.8	26	54.2	0.533**
Metallic taste	3	7.0	3	6.3	
Diarrhea	1	2.3	7	14.6	
Nausea	3	7.0	5	10.4	
Gas	2	4.7	3	6.3	
Vomiting	3	7.0	3	6.3	
Constipation	1	2.3	1	2.1	
Degree of side effects					
None	43	100.	25	52.1	<0.05
Mild			11	22.9	
Moderate			3	6.3	
Severe					
Discontinued treatment			9	18.8	
Eradication ITT analysis					
Yes	38	88.4	33	68.8	0.024*
No	5	11.6	15	31.3	
PP analysissr					
Yes	38	92.7	32	94.1	0.804*
No	5	7.3	2	5.9	

Table 2: Clinical and Demographic Properties of the Study and Control groups.

*Chi-Square statistics at 0.05 significance level

**Mann Whitney-U Test at 0.05 significance level

In the present randomized, open labeled study we used a synbiotic product that and which included lactobacillus, enterococcus, bifidobacterium, and prebiotics. We evaluated whether a PPI-based triple therapy with adjunctive synbiotic administration for

2 weeks increased eradication rates. We determined that the eradication rate in the probiotic group was higher than that of the control group. Prebiotics such as oligofructose may function in a primary antibacterial role by augmenting the growth of beneficial probiotic strains, which has been documented in competition experiments between strains of *E. coli*, *Clostridium perfringens*, and *Bifidobacterium infantis*. A combination of prebiotics and probiotics might have a positive effect on *H. pylori* eradication rates. The majority of previous studies used probiotics in fermented dairy products or food supplements. However, these studies did not achieve desired eradication rates^(9,12,17). *S. boulardii* was the other choice of probiotics in several studies. In 2006, Cindoruk et al. reported that probiotics had no significant effect on *H. pylori* eradication rates⁽¹⁸⁾. Previous studies determined that patients with non-ulcer dyspepsia had significantly lower eradication rates than did patients with non-ulcer dyspepsia. Kadayifci et al. showed a major decrease in eradication rates from 80% to 60% with standard PPI-based triple therapy in an epidemiologic study that included long term analysis⁽¹⁹⁾. In 2004 Aydın et al. reported that *H. pylori* eradication rates with PPI based triple therapy had decreased to 47.1% from 93.3% since 1996⁽²⁰⁾. These two controlled, randomized trials explain that these unsatisfactory eradication rates are a result of the rising prevalence of clarithromycin resistance. Several studies explain that the NUD group has lower eradication rates with a different hypothesis, one being that different levels of inflammation are caused by different strains of *H. pylori*. High inflammation increases vascular and epithelial permeability and might allow antibiotics to better penetrate the gastric lumen. In addition, antibiotic-associated side effects such as diarrhea, nausea, vomiting, bloating and metallic taste may contribute to unsatisfactory eradication rates. Alternative treatment regimens, including probiotics, are being assessed to overcome these problems, and so far conflicting results have been reported^(12,13,21-23).

Probiotics are living, and when administered in adequate amounts confer a health benefit on the host⁽²³⁾. In studies that focus on improving *H. pylori* eradication rates, a mainly used probiotics are *Bifidobacterium* and *Lactobacillus*. Probiotics may act by killing *H. pylori* in vitro or by improving patient compliance to treatment by reducing the incidence of therapy-related adverse effects. Prebiotics, described as “non digestible food ingre-

dients that beneficially affect the host by selectively stimulating the growth and/or activity of one or a limited number of beneficial bacteria in the colon, thereby improving the host’s health” provide an additional mechanism for influencing the population dynamics of the intestinal microflora. Prebiotics are present in significant amounts in a wide variety of fruits and vegetables and are fermented by colonic bacteria to lactic acid and short-chain carboxylic acids. Other oligomers with prebiotic potential are lactulose and sugar alcohols such as mannitol and xylitol⁽²⁴⁾.

Duman et al. aimed to evaluate the efficacy and safety of *Saccharomyces boulardii* (*S. boulardii*) in preventing antibiotic-associated diarrhea in patients receiving antibiotics for *H. pylori* eradication. Patients with peptic ulcer disease or non-ulcer dyspepsia were enrolled to receive clarithromycin, amoxicillin and omeprazole for *H. pylori* eradication for 14 days. These patients were then randomized to receive either 500 mg *S. boulardii* twice daily (treatment group) or no treatment (control group). Overall, diarrhea rates throughout the whole study period were 6.9% in the treatment group and 15.6% in the control group ($p=0.007$) (25). In 2006 Cindoruk et al. reported that *S. boulardii* is an effective and safe treatment for the prevention of antibiotic-associated diarrhea⁽¹⁸⁾.

The recent World Gastroenterology Organization (WGO) guideline on probiotics also stated that probiotics might add positive effects on *H. Pylori* eradication in several aspects, such as decreasing side effects and increasing patient tolerability, increasing immune response⁽²⁶⁾.

In conclusion, the addition of a synbiotic to triple therapy decreases the rate of antibiotic-related side effects. It also increases *H. pylori* eradication rates in clarithromycin-based triple therapy. We suggest that addition of a prebiotic and probiotic combination to triple therapy might be an option to improve *H. pylori* eradication rates. This is a new area of research that needs to be studied with large, randomized, controlled trials.

References

- 1) Vakil N, Malfertheiner P, Chey WD. *Helicobacter pylori* infection. N Engl J Med. 2010; 363: 595.
- 2) Muñoz N. Is *Helicobacter pylori* a cause of gastric cancer? An appraisal of the seroepidemiological evidence. Cancer Epidemiol Biomarkers Prev. 1994; 3: 445-51.

- 3) Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; *European Helicobacter Study Group*. Management of *Helicobacter pylori* infection-the Maastricht IV/ Florence Consensus Report. *Gut*. 2012; 61: 646-64.
- 4) Graham DY, Fischbach L. *Helicobacter pylori* treatment in the era of increasing antibiotic resistance. *Gut*. 2010; 59: 1143-53.
- 5) Seven G, Cinar K, Yakut M, Idilman R, Ozden A. Assessment of *Helicobacter pylori* eradication rate of triple combination therapy containing levofloxacin. *Turk J Gastroenterol*. 2011; 22: 582-6.
- 6) Taş A, Akbal E, Koçak E, Köklü S. Moxifloxacin-tetracycline-lansoprazole triple therapy for first-line treatment of *Helicobacter pylori* infection: a prospective study. *Helicobacter*. 2011; 16: 52-4.
- 7) Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during *Helicobacter pylori* eradication therapy. *Aliment Pharmacol Ther*. 2007; 25: 155-68.
- 8) Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; *European Helicobacter Study Group*. Management of *Helicobacter pylori* infection-the Maastricht IV/ Florence Consensus Report. *Gut*. 2012; 61: 646-64.
- 9) Yoon H, Kim N, Kim JY, Park SY, Park JH, Jung HC, Song IS. Effects of multistrain probiotic-containing yogurt on second-line triple therapy for *Helicobacter pylori* infection. *J Gastroenterol Hepatol*. 2011; 26: 44-8.
- 10) Johnson-Henry KC, Mitchell DJ, Avitzur Y, Galindo-Mata E, Jones NL, Sherman PM. Probiotics reduce bacterial colonization and gastric inflammation in *H. pylori*-infected mice. *Dig Dis Sci*. 2004; 49: 1095-102.
- 11) Kim MN, Kim N, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Kim JS, Jung HC, Song IS. The effects of probiotics on PPI-triple therapy for *Helicobacter pylori* eradication. *Helicobacter*. 2008; 13: 261-8.
- 12) Sachdeva A, Nagpal J. Effect of fermented milk-based probiotic preparations on *Helicobacter pylori* eradication: a systematic review and meta-analysis of randomized-controlled trials. *Eur J Gastroenterol Hepatol*. 2009; 21: 45-53.
- 13) Zou J, Dong J, Yu X. Meta-analysis: *Lactobacillus* containing quadruple therapy versus standard triple first-line therapy for *Helicobacter pylori* eradication. *Helicobacter*. 2009; 14: 97-107.
- 14) Guarner F. Prebiotics, probiotics and helminths: the 'natural' solution? *Dig Dis*. 2009; 27: 412-7.
- 15) Erçin CN, Uygun A, Toros AB, Kantarcioğlu M, Kilciler G, Polat Z, Bağcı S. Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with *Helicobacter pylori* positive non-ulcer dyspepsia. *Turk J Gastroenterol*. 2010; 21: 12-6.
- 16) Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, Vaz Coelho LG, Fock M, Fedail S, Cohen H, Malfertheiner P, Vakil N, Hamid S, Goh KL, Wong BC, Krabshuis J, Le Mair A; *World Gastroenterology Organization*. *Helicobacter pylori* in developing countries. *World Gastroenterology Organisation Global Guideline*. *J Gastrointest Liver Dis*. 2011 Sep; 20: 299-304.
- 17) Yaşar B, Abut E, Kayadibi H, Toros B, Sezıklı M, Akkan Z, Keskin Ö, Övünç Kurdaş O. Efficacy of probiotics in *Helicobacter pylori* eradication therapy. *Turk J Gastroenterol*. 2010 Sep; 21(3): 212-7. PubMed PMID: 20931422.
- 18) Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S. Efficacy and safety of *Saccharomyces boulardii* in the 14-day triple anti-*Helicobacter pylori* therapy: a prospective randomized placebo-controlled double-blind study. *Helicobacter*. 2007; 12: 309-16.
- 19) Uygun A, Kadayifçi A, Yeşilova Z, Savaş MC, Ateş Y, Karslıoğlu Y, Çiğirim M, Bağcı S, Dağalp K. Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of *Helicobacter pylori*. *Turk J Gastroenterol*. 2004; 15: 219-24.
- 20) Aydın F, Kaklıkkaya N, Özgür O, Cubukcu K, Kilic AO, Tosun I, Ertürk M. Distribution of *vacA* alleles and *cagA* status of *Helicobacter pylori* in peptic ulcer disease and non-ulcer dyspepsia. *Clin Microbiol Infect*. 2004; 10: 1102-4.
- 21) Heineman J, Bubenik S, McClave S, Martindale R. Fighting fire with fire: is it time to use probiotics to manage pathogenic bacterial diseases? *Curr Gastroenterol Rep*. 2012; 14: 343-8.
- 22) Girardin M, Seidman EG. Indications for the use of probiotics in gastrointestinal diseases. *Dig Dis*. 2011; 29: 574-87.
- 23) Cremonini F, Canducci F, Di Caro S, Santarelli L, Armuzzi A, Gasbarrini G, Gasbarrini A. *Helicobacter pylori* treatment: a role for probiotics? *Dig Dis*. 2001; 19: 144-7.
- 24) Thomas DW, Greer FR; *American Academy of Pediatrics Committee on Nutrition; American Academy of Pediatrics Section on Gastroenterology, Hepatology, and Nutrition*. Probiotics and prebiotics in pediatrics. *Pediatrics*. 2010; 126: 1217-31.
- 25) Duman DG, Bor S, Özütmez O, Sahin T, Oğuz D, Iştan F, Vural T, Sandkci M, Işksal F, Simşek I, Soyutürk M, Arslan S, Sivri B, Soykan I, Temizkan A, Beşşık F, Kaymakoglu S, Kalaycı C. Efficacy and safety of *Saccharomyces boulardii* in prevention of antibiotic-associated diarrhoea due to *Helicobacter pylori* eradication. *Eur J Gastroenterol Hepatol*. 2005; 17: 1357-61.
- 26) Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A, Krabshuis J, Lemair T, Kaufmann P, de Paula JA, Fedorak R, Shanahan F, Sanders ME, Szajewska H, Ramakrishna BS, Karakan T, Kim N; *World Gastroenterology Organization*. *World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics* October 2011. *J Clin Gastroenterol*. 2012; 46: 468-81.

Request reprints from:

EBUBEKİR ŞENATEŞ, MD
University Medical Faculty
Department of Gastroenterology
Diyarbakir
(Turkey)